- Conditions
- APOL1-mediated Kidney Disease
- Interventions
- APOL1 Genotyping
- Diagnostic Test
- Lead sponsor
- Almac Diagnostic Services LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Proteinuric Kidney Disease
- Interventions
- MZE829
- Drug
- Lead sponsor
- Maze Therapeutics
- Industry
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 68
- States / cities
- Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 56 more
- Conditions
- APOL1-Mediated Kidney Disease
- Interventions
- AZD2373-Arm 1, AZD2373-Arm 2, Placebo, APOL1 Genotyping Clinical Trial Assay
- Combination Product · Device
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 86
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Irondale, Alabama + 73 more
- Conditions
- Proteinuric Kidney Disease
- Interventions
- Inaxaplin
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 67 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 35
- States / cities
- Huntsville, Alabama • Hollywood, Florida • Lauderdale Lakes, Florida + 28 more
- Conditions
- Proteinuric Kidney Disease
- Interventions
- VX-147, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 10 Years to 65 Years
- Enrollment
- 522 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 223
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Fairhope, Alabama + 144 more
- Conditions
- Glomerulosclerosis, Focal Segmental
- Interventions
- VX-147
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 25 more
- Conditions
- APOL1-mediated Kidney Disease
- Interventions
- VX-840, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas